X hits on this document

222 views

0 shares

0 downloads

0 comments

42 / 61

Clinical Trials

LIDO Trial

Levosimendan 24 hr infiusionvs Dobutamine

203 Patients

Severe Decompensated HF, AHF, HF after CABG

Excluded if cardiogenic shock

Endpoints, increased CI (35% vs 25%) and reduced PCWP (28% vs 15%) in favor of Levosimendan

SURVIVE Trial

Levosimendan vs Dobutamine 24 hour therapy

1327 patients

Endpoints symptomatic relief and BNP

Levosimendan Greater reduction in BNP but no difference in symptomatic relief

Document info
Document views222
Page views222
Page last viewedMon Jan 23 21:10:16 UTC 2017
Pages61
Paragraphs503
Words1542

Comments